Protalix BioTherapeutics Inc. has released a corporate presentation detailing its current pipeline and financial status. The company reported $53 million in revenue for the full year 2024 and $25.4 million in revenue from product sales in the first half of 2025. As of June 30, 2025, Protalix holds $33.4 million in cash with no debt or warrants, supporting its operations and pipeline development into 2027. Protalix highlighted its commercial portfolio, which includes approved enzyme replacement therapies for Fabry disease and Gaucher disease in the United States, European Union, and additional markets. The development portfolio features PRX-115, a PEGylated uricase candidate targeting uncontrolled gout, with a Phase 2 trial expected to begin in the fourth quarter of 2025. The company is also advancing PRX-119, a long-acting DNase I, and is pursuing additional programs in rare renal and NETs-related diseases. Over the next three years, Protalix aims to expand its pipeline to five to seven programs spanning discovery to clinical stages. You can access the full presentation through the link below.